Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E Lominska

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 16, 2019
The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiationRohit G Ganju, Ryan Morse, Andrew Hoover, et al.
American Journal of Clinical Oncology|September 15, 2025
Logistic Model in Clinical and Health Research-the Elephant and Blind MenYing Cao, Aaron J Katz, Xinglei Shen, et al.
Cancers|May 14, 2022
Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict FrailtyRyan T Morse, Rohit G Ganju, Gregory N Gan, et al.
Head & Neck|November 11, 2020
What is the hold up?-Mixed-methods analysis of postoperative radiotherapy delay in head and neck cancerKevin J Sykes, Emily Morrow, Joshua B Smith, et al.
Head & Neck|March 12, 2019
Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinomaRyan T Morse, Rohit G Ganju, Mindi J TenNapel, et al.
Chemotherapy|July 26, 2022
Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent ChemoradiotherapyRyan T Morse, Rohit G Ganju, Rishi Neeranjun, et al.
Neurosurgery|September 10, 2011
Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomasKeith R Unger, Christopher E Lominska, June Chanyasulkit, et al.
Molecular Carcinogenesis|September 24, 2021
Mitogen-activated protein kinase-activated protein kinase-2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancerDeri Morgan, Kiersten L Berggren, Colby D Spiess, et al.
The American Surgeon|July 2, 2026
Complete Response of Merkel Cell Carcinoma to Immunotherapy and Single-Fraction Radiotherapy Following Severe COVID-19 Infection: A Case Report and Review of Immune MechanismAubrey C Swilling, Jessica Caraway, Thomas M Irwin, et al.
Head & Neck|May 15, 2014
Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large seriesMarie-Adele S Kress, Neilayan Sen, Keith R Unger, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 16, 2019
The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiationRohit G Ganju, Ryan Morse, Andrew Hoover, et al.
American Journal of Clinical Oncology|September 15, 2025
Logistic Model in Clinical and Health Research-the Elephant and Blind MenYing Cao, Aaron J Katz, Xinglei Shen, et al.
Cancers|May 14, 2022
Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict FrailtyRyan T Morse, Rohit G Ganju, Gregory N Gan, et al.
Head & Neck|November 11, 2020
What is the hold up?-Mixed-methods analysis of postoperative radiotherapy delay in head and neck cancerKevin J Sykes, Emily Morrow, Joshua B Smith, et al.
Head & Neck|March 12, 2019
Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinomaRyan T Morse, Rohit G Ganju, Mindi J TenNapel, et al.
Chemotherapy|July 26, 2022
Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent ChemoradiotherapyRyan T Morse, Rohit G Ganju, Rishi Neeranjun, et al.
Neurosurgery|September 10, 2011
Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomasKeith R Unger, Christopher E Lominska, June Chanyasulkit, et al.
Molecular Carcinogenesis|September 24, 2021
Mitogen-activated protein kinase-activated protein kinase-2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancerDeri Morgan, Kiersten L Berggren, Colby D Spiess, et al.
The American Surgeon|July 2, 2026
Complete Response of Merkel Cell Carcinoma to Immunotherapy and Single-Fraction Radiotherapy Following Severe COVID-19 Infection: A Case Report and Review of Immune MechanismAubrey C Swilling, Jessica Caraway, Thomas M Irwin, et al.
Head & Neck|May 15, 2014
Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large seriesMarie-Adele S Kress, Neilayan Sen, Keith R Unger, et al.
Pageof 2